OCEA vs. APVO, ATHX, ATXI, VIRX, KZIA, SYRS, BIOR, CAPS, VRPX, and TFFP
Should you be buying Ocean Biomedical stock or one of its competitors? The main competitors of Ocean Biomedical include Aptevo Therapeutics (APVO), Athersys (ATHX), Avenue Therapeutics (ATXI), Viracta Therapeutics (VIRX), Kazia Therapeutics (KZIA), Syros Pharmaceuticals (SYRS), Biora Therapeutics (BIOR), Capstone (CAPS), Virpax Pharmaceuticals (VRPX), and TFF Pharmaceuticals (TFFP).
Ocean Biomedical vs.
Ocean Biomedical (NASDAQ:OCEA) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
Aptevo Therapeutics received 195 more outperform votes than Ocean Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ocean Biomedical an outperform vote while only 50.00% of users gave Aptevo Therapeutics an outperform vote.
24.6% of Ocean Biomedical shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 73.5% of Ocean Biomedical shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Ocean Biomedical had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for Ocean Biomedical and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.89 beat Ocean Biomedical's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.
Aptevo Therapeutics has higher revenue and earnings than Ocean Biomedical.
Aptevo Therapeutics has a consensus target price of $10,952.00, indicating a potential upside of 2,066,315.09%. Given Aptevo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aptevo Therapeutics is more favorable than Ocean Biomedical.
Ocean Biomedical's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.
Ocean Biomedical has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.75, indicating that its stock price is 475% more volatile than the S&P 500.
Summary
Aptevo Therapeutics beats Ocean Biomedical on 9 of the 14 factors compared between the two stocks.
Get Ocean Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocean Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:OCEA) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy OCEA Stock Free OCEA Stock Alerts